Rho J Inhibitors
Rho J inhibitors are a class of chemical compounds that target the RhoJ protein, a member of the Rho family of small GTPases. RhoJ plays an important role in regulating the dynamics of the actin cytoskeleton, which is crucial for various cellular processes, such as cell shape, motility, and adhesion. As a small GTPase, RhoJ acts as a molecular switch, cycling between an active GTP-bound state and an inactive GDP-bound state. In its active form, RhoJ influences the organization of actin filaments and interacts with various downstream effectors to mediate changes in cytoskeletal architecture. By inhibiting RhoJ, these compounds interfere with the signaling pathways that control cytoskeletal dynamics, potentially affecting processes like cell migration and vascular network formation.
The mechanism of action for RhoJ inhibitors typically involves preventing the activation of RhoJ by either blocking its GTP-binding site or disrupting its interaction with guanine nucleotide exchange factors (GEFs), which facilitate the transition to its active state. This inhibition halts RhoJ's ability to regulate actin organization, leading to impaired cell movement and structural integrity. RhoJ inhibitors are valuable tools for studying the molecular mechanisms behind cytoskeletal rearrangement and its broader implications in cellular behavior. By exploring how these inhibitors affect RhoJ activity, researchers can better understand the intricate signaling networks that govern cell shape, adhesion, and movement, particularly in contexts such as angiogenesis, where RhoJ plays a significant role in endothelial cell dynamics.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Simvastatin | 79902-63-9 | sc-200829 sc-200829A sc-200829B sc-200829C | 50 mg 250 mg 1 g 5 g | $31.00 $89.00 $135.00 $443.00 | 13 | |
Simvastatin could downregulate Rho J expression by inhibiting the mevalonate pathway, crucial for the synthesis of isoprenoids, which are necessary for Rho protein function. | ||||||
Lovastatin | 75330-75-5 | sc-200850 sc-200850A sc-200850B | 5 mg 25 mg 100 mg | $29.00 $90.00 $339.00 | 12 | |
Lovastatin may reduce the expression levels of Rho J by blocking the production of mevalonic acid, thereby hindering the post-translational prenylation of Rho GTPases. | ||||||
Y-27632 dihydrochloride | 129830-38-2 | sc-216067 sc-216067A | 1 mg 5 mg | $170.00 $439.00 | 5 | |
Y-27632 has the potential to decrease Rho J expression by inhibiting Rho-associated kinase (ROCK), which could lead to a downstream reduction in Rho protein transcription. | ||||||
CCG-1423 | 285986-88-1 | sc-205241 sc-205241A | 1 mg 5 mg | $30.00 $90.00 | 8 | |
CCG-1423 could suppress Rho J expression by targeting the serum response factor (SRF), a transcription factor that can control the synthesis of Rho proteins. | ||||||
Rhosin | 1173671-63-0 | sc-507401 | 25 mg | $555.00 | ||
Rhosin may specifically inhibit the expression of Rho J by directly antagonizing RhoA GTPase, potentially leading to a compensatory decrease in Rho J levels. | ||||||
Mevastatin (Compactin) | 73573-88-3 | sc-200853 sc-200853A | 10 mg 50 mg | $77.00 $179.00 | 18 | |
Mevastatin (Compactin) could prevent Rho J expression by impairing the biosynthesis of intermediate products used in the prenylation process, which is essential for Rho protein localization. | ||||||
NSC 23766 | 733767-34-5 | sc-204823 sc-204823A | 10 mg 50 mg | $151.00 $609.00 | 75 | |
NSC23766 could reduce the cellular levels of Rho J by inhibiting the guanine nucleotide exchange factor (GEF) specific for Rac1, potentially altering Rho GTPase activity. | ||||||
ML 141 | 71203-35-5 | sc-362768 sc-362768A | 5 mg 25 mg | $137.00 $512.00 | 7 | |
ML 141 may lead to a decreased expression of Rho J by inhibiting Cdc42, another member of the Rho GTPase family, thus disrupting the balance within the Rho GTPase network. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 could attenuate the expression of Rho J by inhibiting phosphoinositide 3-kinases (PI3K), which play a role in the signaling pathways that control gene transcription. | ||||||
Zoledronic acid, anhydrous | 118072-93-8 | sc-364663 sc-364663A | 25 mg 100 mg | $92.00 $256.00 | 5 | |
Zoledronic acid may lead to a reduction in Rho J protein levels by targeting farnesyl pyrophosphate synthase, an enzyme necessary for the prenylation of many proteins. | ||||||